Dual targeting multiwalled carbon nanotubes for improved neratinib delivery in breast cancer

Lila, Amr S. Abu; Bhattacharya, Rohini; Moin, Afrasim; Hagbani, Turki Al; Abdallah, Marwa H.; Rizvi, Syed Mohd Danish; Khafagy, El-Sayed; Hussain, Talib; Gangadharappa, H.V.

doi:10.1039/d3ra04732f

RSC Adv.

2023

DOI: 10.1039/d3ra04732f

|View full text |Cite

Dual targeting multiwalled carbon nanotubes for improved neratinib delivery in breast cancer

Amr S. Abu Lila

Rohini Bhattacharya

Afrasim Moin

et al.

Abstract: The aim of this study was to develop biotinylated chitosan (Bio–Chi) decorated multi-walled carbon nanotubes (MWCNTs) for breast cancer therapy with the tyrosine kinase inhibitor, neratinib (NT).

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 6 publications

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Deciphering the landscape of triple negative breast cancer from microenvironment dynamics and molecular insights to biomarker analysis and therapeutic modalities

Tiwari,

Singh,

Sharma

et al. 2024

Medicinal Research Reviews

View full text Add to dashboard Cite

Triple negative breast cancer (TNBC) displays a notable challenge in clinical oncology due to its invasive nature which is attributed to the absence of progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor (HER‐2). The heterogenous tumor microenvironment (TME) of TNBC is composed of diverse constituents that intricately interact to evade immune response and facilitate cancer progression and metastasis. Based on molecular gene expression, TNBC is classified into four molecular subtypes: basal‐like (BL1 and BL2), luminal androgen receptor (LAR), immunomodulatory (IM), and mesenchymal. TNBC is an aggressive histological variant with adverse prognosis and poor therapeutic response. The lack of response in most of the TNBC patients could be attributed to the heterogeneity of the disease, highlighting the need for more effective treatments and reliable prognostic biomarkers. Targeting certain signaling pathways and their components has emerged as a promising therapeutic strategy for improving patient outcomes. In this review, we have summarized the interactions among various components of the dynamic TME in TNBC and discussed the classification of its molecular subtypes. Moreover, the purpose of this review is to compile and provide an overview of the most recent data about recently discovered novel TNBC biomarkers and targeted therapeutics that have proven successful in treating metastatic TNBC. The emergence of novel therapeutic strategies such as chemoimmunotherapy, chimeric antigen receptor (CAR)‐T cells‐based immunotherapy, phytometabolites‐mediated natural therapy, photodynamic and photothermal approaches have made a significant positive impact and have paved the way for more effective interventions.

show abstract

Deciphering the landscape of triple negative breast cancer from microenvironment dynamics and molecular insights to biomarker analysis and therapeutic modalities

Tiwari,

Singh,

Sharma

et al. 2024

Medicinal Research Reviews

View full text Add to dashboard Cite

show abstract

Exploring the therapeutic applications of nano-therapy of encapsulated cisplatin and anthocyanin-loaded multiwalled carbon nanotubes coated with chitosan-conjugated folic acid in targeting breast and liver cancers

Awad,

Hanafy,

Ali

et al. 2024

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

Implications of nanotherapeutic advancements to leverage multi-drug resistant breast cancer: The state-of-the-art review

Aravindan,

Gupta,

Moorkoth

et al. 2024

Journal of Drug Delivery Science and Technology

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Dual targeting multiwalled carbon nanotubes for improved neratinib delivery in breast cancer

Abstract: The aim of this study was to develop biotinylated chitosan (Bio–Chi) decorated multi-walled carbon nanotubes (MWCNTs) for breast cancer therapy with the tyrosine kinase inhibitor, neratinib (NT).

Cited by 6 publications

References 52 publications

Deciphering the landscape of triple negative breast cancer from microenvironment dynamics and molecular insights to biomarker analysis and therapeutic modalities

Deciphering the landscape of triple negative breast cancer from microenvironment dynamics and molecular insights to biomarker analysis and therapeutic modalities

Exploring the therapeutic applications of nano-therapy of encapsulated cisplatin and anthocyanin-loaded multiwalled carbon nanotubes coated with chitosan-conjugated folic acid in targeting breast and liver cancers

Implications of nanotherapeutic advancements to leverage multi-drug resistant breast cancer: The state-of-the-art review

Contact Info

Product

Resources

About